Neutral
Profund Advisors LLC grew its position in Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) by 209.3% in the 4th quarter, according to the compan...
Neutral
Profund Advisors LLC increased its stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) by 209.3% during the fourth quarter, acco...
Bullish
Travere Therapeutics successfully completed a public offering of $525 million in 0.50% Convertible Senior Notes due 2032, generating approximately $50...
Neutral
Travere Therapeutics, Inc. announced its participation in three upcoming investor conferences in May and June 2026: the BofA Securities 2026 Health Ca...
Neutral
Travere Therapeutics announced its intention to offer $400 million in convertible senior notes due 2032, with an option for underwriters to purchase a...
Bullish
Travere Therapeutics announced its first-quarter 2026 financial results, highlighted by the FDA approval of FILSPARI for FSGS, significantly expanding...
Bullish
This page provides access to Travere Therapeutics Inc. (TVTX) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms, enhanced with AI-powe...
Vanguard Capital Management has disclosed beneficial ownership of 4,699,424 shares, representing a 5.09% stake in Travere Therapeutics (NASDAQ: TVTX),...